Is Abbott's Established Pharmaceuticals segment growing steadily?

Abbott's Established Pharmaceuticals segment appears to be growing steadily, as evidenced by the positive year-over-year revenue growth rate of 7.16%. This indicates a strong performance and suggests that the segment is likely contributing positively to the company's overall financial performance.

|code|Ticker|Name|Date|Net Income YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|ABT|ABT.N|Abbott Laboratories|2024 Q1|-7.0561456752655545|9.964E9|169|
|ABT|ABT.N|Abbott Laboratories|2024 Q2|-5.3090909090909095|1.0377E10|169|
|ABT|ABT.N|Abbott Laboratories|2024 Q3|14.623955431754876|1.0635E10|169|
|ABT|ABT.N|Abbott Laboratories|2024 Q4|478.98368883312423|1.0974E10|169|